Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of SSR149744c 100 or 300 mg for the Prevention of ventrICular ARrhythmia-triggered Icd interventiOnS
Primary objective:

 -  to assess the efficacy of SSR149744C for the prevention of ventricular
 arrhythmia-triggered ICD interventions.

 Secondary objectives:

 -  to assess versus placebo the tolerability of the different dose regimens of SSR149744C
 in the selected population.

 -  to document SSR149744C plasma level during the study.
Inclusion Criteria:

 -  Patient with an ICD implanted during the previous year for documented spontaneous
 life-threatening ventricular arrhythmia OR implanted with an ICD and with at least one
 appropriate ICD therapy (shock or anti-tachycardia pacing) for ventricular tachycardia
 or ventricular fibrillation in the previous year.

 -  Left ventricular ejection fraction measured by 2D-echocardiography must have been
 documented to be less than 40% in the last 6 months.

 Exclusion Criteria:

 MAIN CRITERIA (non-exhaustive list):

 -  Women of childbearing potential without adequate birthcontrol, Pregnant Women,
 Breastfeeding women, conditions which increase the risk of severe antiarrhythmic drug
 side effects, severe associated conditions.